Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 766 to 780 of 2184 results for guidelines

  1. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.

  2. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.

  3. Myocardial infarction: medication for MI in preceding 12 months (IND125)

    This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79

  4. Diabetes: annual general practice checks (IND120)

    This indicator covers the percentage of patients with diabetes who have had the following care processes performed in the preceding 12 months: BMI measurement, BP measurement, HbA1c measurement, cholesterol measurement, record of smoking status, foot examination, albumin:creatinine ratio, eGFR creatinine measurement. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM74

  5. Mortality: liver disease (IND282)

    This indicator covers under 75 mortality from liver disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  6. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

  7. DMD Care UK's guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations: NICE review (NG251)

    We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See NICE review 1 on DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.

  8. Stage 3: admission to the system

    In virtual wards, patients remain at home to receive hospital-level care. Our guidance can help you determine if patients are suitable for admission to the virtual wards system.

  9. Mortality: cardiovascular disease (IND280)

    This indicator covers under 75 mortality from cardiovascular disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  10. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date:  12 August 2026

  11. NICE quality standards: process guide (PMG43)

    This guide describes the process NICE uses to develop NICE quality standards

  12. Mortality: respiratory (IND281)

    This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  13. Forward view - our priority topics

    Our forward view highlights the topics we will prioritise in the coming year.

  14. Sole supplied titles

    Sole supplied titles are distinct journal and book collections that can be purchased from Lot 1 of our purchasing framework.

  15. Infections: scoring tools for sore throat (IND323)

    This indicator covers the percentage of diagnoses of sore throat in the preceding 12 months with a recorded FeverPain or Centor score. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes